Business, energy, technology, markets and global industry news from Business News Today

cemiplimab

PharmaDeviceNews cemiplimab
Representative image: Clinician reviewing lung CT scans, reflecting MAIA Biotechnology’s ateganosine data in third-line non-small cell lung cancer and the evolving search for new NSCLC treatment strategies.
Pharma & Biotech

MAIA Biotechnology reports stronger ateganosine data in third-line non-small cell lung cancer

MAIA Biotechnology has reported positive initial efficacy data from Part C of the Phase 2 THIO-101 expansion trial evaluating ateganosine followed by cemiplimab in third-line advanced non-small cell lung cancer. The clinical-stage oncology drug developer said the regimen produced a 90.5 percent interim disease control rate among efficacy-evaluable patients, placing its telomere-targeting strategy back in

Read More
Pharma & Biotech

Can Biohaven’s BHV-1510 avoid the safety pitfalls of existing Trop2 ADCs in solid tumors?

Biohaven Ltd. presented updated Phase 1 clinical data on BHV-1510, its next-generation Trop2-targeting antibody-drug conjugate, at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London. The results, derived from a heavily pretreated population with advanced or metastatic solid tumors, showed encouraging response rates across non-small cell lung cancer, endometrial cancer, and urothelial

Read More